DE20007303U1 - Kristalline Base von Citalopram - Google Patents

Kristalline Base von Citalopram

Info

Publication number
DE20007303U1
DE20007303U1 DE20007303U DE20007303U DE20007303U1 DE 20007303 U1 DE20007303 U1 DE 20007303U1 DE 20007303 U DE20007303 U DE 20007303U DE 20007303 U DE20007303 U DE 20007303U DE 20007303 U1 DE20007303 U1 DE 20007303U1
Authority
DE
Germany
Prior art keywords
citalopram
base
salt
crystalline
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE20007303U
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8159320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE20007303(U1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of DE20007303U1 publication Critical patent/DE20007303U1/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Laminated Bodies (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)

Description

Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt

Claims (10)

1. Kristalline Base der Verbindung Citalopram (1-[3-(Dimethylamino)propyl]-1-(4-fluorphenyl)-1,3- dihydro-5-isobenzofurancarbonitril) mit der Formel:
2. Kristalline Base gemäß Anspruch 1, dadurch gekennzeichnet, daß die Base die racemische Mischung von Citalopram ist.
3. Kristalline Base gemäß Anspruch 1 oder 2, dadurch gekennzeichnet, daß sie einen Schmelzpunkt von 90 bis 93°C besitzt, am meisten bevorzugt 91 bis 92°C.
4. Kristalline Base gemäß einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, daß sie eine Reinheit von mehr als 99,8 Gew.-% besitzt, vorzugsweise mehr als 99,9 Gew.-%.
5. Kristallines Salz von Citalopram, hergestellt durch Freisetzen der Base von Citalopram, Ausfällen der Base in kristalliner Form und Überführen in das Salz.
6. Kristallines Salz, hergestellt durch Freisetzen der Base von Citalopram aus einem rohen Salz von Citalopram, Ausfällen der Base in kristalliner Form und Überführen in das Salz.
7. Kristallines Salz, hergestellt durch Freisetzen der Base von Citalopram aus einer Rohlösung von Citalopram-Base oder -Salz, Ausfällen der Base in kristalliner Form und Überführen in das Salz.
8. Kristallines Salz gemäß einem der Ansprüche 5 bis 7, dadurch gekennzeichnet, daß es das Hydrobromid- oder Hydrochloridsalz von Citalopram ist.
9. Hydrochlorid- oder Hydrobromidsalz von Citalopram gemäß Anspruch 8, dadurch gekennzeichnet, daß es eine Reinheit von mehr als 99,8 Gew.-% besitzt, vorzugsweise mehr als 99,9 Gew.-%.
10. Pharmazeutische Formulierung der freien Base von Citalopram gemäß einem der Ansprüche 1 bis 4, vorzugsweise Tabletten oder ein Schmelzgranulat.
DE20007303U 2000-03-13 2000-04-20 Kristalline Base von Citalopram Ceased DE20007303U1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200000402 2000-03-13

Publications (1)

Publication Number Publication Date
DE20007303U1 true DE20007303U1 (de) 2000-07-27

Family

ID=8159320

Family Applications (7)

Application Number Title Priority Date Filing Date
DE20007303U Ceased DE20007303U1 (de) 2000-03-13 2000-04-20 Kristalline Base von Citalopram
DE10164687A Revoked DE10164687B4 (de) 2000-03-13 2001-02-20 Verfahren zur Herstellung von gereinigter Citalopram-Base oder eines gereinigten Salzes von Citalopram
DE20121240U Ceased DE20121240U1 (de) 2000-03-13 2001-02-20 Kristalline Citalopram-Base
DE10108042A Withdrawn DE10108042A1 (de) 2000-03-13 2001-02-20 Kristalline Citalopram-Base
DE60100786T Revoked DE60100786T2 (de) 2000-03-13 2001-02-28 Kristalline Base von Citalopram, und Hydrochlorid- oder Hydrobromidsalz davon
DE1227088T Pending DE1227088T1 (de) 2000-03-13 2001-02-28 Kristalline Base von Citalopram, und Hydrochlorid- oder Hydrobromidsalz davon
DE60100022T Expired - Fee Related DE60100022T3 (de) 2000-03-13 2001-02-28 Verfahren zur herstellung von citalopram-salzen

Family Applications After (6)

Application Number Title Priority Date Filing Date
DE10164687A Revoked DE10164687B4 (de) 2000-03-13 2001-02-20 Verfahren zur Herstellung von gereinigter Citalopram-Base oder eines gereinigten Salzes von Citalopram
DE20121240U Ceased DE20121240U1 (de) 2000-03-13 2001-02-20 Kristalline Citalopram-Base
DE10108042A Withdrawn DE10108042A1 (de) 2000-03-13 2001-02-20 Kristalline Citalopram-Base
DE60100786T Revoked DE60100786T2 (de) 2000-03-13 2001-02-28 Kristalline Base von Citalopram, und Hydrochlorid- oder Hydrobromidsalz davon
DE1227088T Pending DE1227088T1 (de) 2000-03-13 2001-02-28 Kristalline Base von Citalopram, und Hydrochlorid- oder Hydrobromidsalz davon
DE60100022T Expired - Fee Related DE60100022T3 (de) 2000-03-13 2001-02-28 Verfahren zur herstellung von citalopram-salzen

Country Status (42)

Country Link
US (7) US20010031784A1 (de)
EP (2) EP1227088B1 (de)
JP (1) JP2003527383A (de)
KR (1) KR20020080486A (de)
CN (2) CN1680350A (de)
AR (1) AR029811A1 (de)
AT (3) ATE250050T1 (de)
AU (2) AU746664B2 (de)
BE (1) BE1013210A3 (de)
BG (1) BG107065A (de)
BR (1) BR0109373A (de)
CA (2) CA2360287C (de)
CH (2) CH691477A5 (de)
CZ (1) CZ292077B6 (de)
DE (7) DE20007303U1 (de)
DK (3) DK173903B1 (de)
EA (1) EA200200972A1 (de)
ES (3) ES2173054T3 (de)
FI (2) FI20010156A0 (de)
FR (1) FR2806086B1 (de)
GB (2) GB2357762B (de)
GR (1) GR1003796B (de)
HK (1) HK1054750A1 (de)
HR (1) HRP20020756A2 (de)
HU (3) HU0001581D0 (de)
IE (1) IES20010109A2 (de)
IL (2) IL147339A (de)
IS (1) IS5841A (de)
IT (2) IT1319645B1 (de)
MX (1) MXPA02008793A (de)
NL (2) NL1016435C1 (de)
NO (2) NO312031B1 (de)
PL (1) PL360158A1 (de)
PT (2) PT1227088E (de)
SE (2) SE517136C2 (de)
SI (2) SI1227088T1 (de)
SK (1) SK285528B6 (de)
TR (1) TR200202185T2 (de)
UA (1) UA74360C2 (de)
WO (1) WO2001068627A1 (de)
YU (1) YU68802A (de)
ZA (1) ZA200207148B (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2806086A1 (fr) * 2000-03-13 2001-09-14 Lundbeck & Co As H Base cristalline du citalopram
EP1152000A1 (de) * 2000-05-02 2001-11-07 SUMIKA FINE CHEMICALS Co., Ltd. Citalopramhydrobromidkristall und deren kristallisierungsverfahren
EP1462447A2 (de) * 2000-12-22 2004-09-29 H. Lundbeck A/S Verfahren zur Herstellung von reinem Citalopram
WO2004094399A1 (en) * 2003-04-21 2004-11-04 Natco Pharma Ltd An improved process for the preparation of citalopram hydrobromide
US7560576B2 (en) 2005-06-22 2009-07-14 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE237604T1 (de) * 1999-04-14 2003-05-15 Lundbeck & Co As H Verfahren zur herstellung von citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US7708749B2 (en) 2000-12-20 2010-05-04 Fox Hollow Technologies, Inc. Debulking catheters and methods
US8328829B2 (en) 1999-08-19 2012-12-11 Covidien Lp High capacity debulking catheter with razor edge cutting window
US7713279B2 (en) 2000-12-20 2010-05-11 Fox Hollow Technologies, Inc. Method and devices for cutting tissue
US6299622B1 (en) 1999-08-19 2001-10-09 Fox Hollow Technologies, Inc. Atherectomy catheter with aligned imager
US7887556B2 (en) 2000-12-20 2011-02-15 Fox Hollow Technologies, Inc. Debulking catheters and methods
IES20010157A2 (en) 2000-03-03 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
IES20010206A2 (en) 2000-03-13 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
AR032455A1 (es) 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
IS6021A (is) * 2000-08-10 2001-10-20 H. Lundbeck A/S Lyfjasamsetningar sem innihalda sítalópram
GB2376233B (en) * 2000-08-10 2003-09-10 Lundbeck & Co As H Crystals of a pharmaceutically acceptable salt of citalopram wherein the median size of the crystals is at least 40 microns
ES2436668T3 (es) 2000-12-20 2014-01-03 Covidien Lp Catéter para retirar material oclusivo ateromatoso o trombótico
AU2001100195B4 (en) * 2001-01-05 2001-12-20 H Lundbeck As Pharmaceutical composition containing citalopram.
GB0105627D0 (en) * 2001-03-07 2001-04-25 Cipla Ltd Preparation of phthalanes
IL158031A0 (en) * 2001-05-01 2004-03-28 Lundbeck & Co As H The use of enantiomeric pure escitalopram
DE60217932T2 (de) 2001-07-31 2007-08-30 H. Lundbeck A/S, Valby Kristalline Zusammensetzung enthaltend Escitalopram
AU2003222435A1 (en) * 2002-01-07 2003-07-24 Sun Pharmaceutical Industries Limited Process for the preparation of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
GB2385848A (en) * 2002-02-27 2003-09-03 Cipla Ltd Citalopram salts
GB2386118A (en) * 2002-02-27 2003-09-10 Cipla Ltd Citalopram
GB0204607D0 (en) 2002-02-27 2002-04-10 Matrix Lab Ltd Process
GB2387596B (en) * 2002-02-27 2004-02-11 Matrix Lab Ltd Process
GB2386119A (en) * 2002-02-27 2003-09-10 Cipla Ltd Purification of citalopram
EP1346989A1 (de) * 2002-03-21 2003-09-24 Jubilant Organosys Limited Verbessertes Verfahren zur Herstellung von Citalopram und Citalopram Hydrobromid
GB0206708D0 (en) * 2002-03-21 2002-05-01 Cipla Ltd Pharmaceutical salts
US6812355B2 (en) 2002-10-22 2004-11-02 Sekhsaria Chemicals Limited Process for the manufacture of citalopram hydrobromide from 5-bromophthalide
US20050154052A1 (en) * 2003-03-24 2005-07-14 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US8246640B2 (en) 2003-04-22 2012-08-21 Tyco Healthcare Group Lp Methods and devices for cutting tissue at a vascular location
US7019153B2 (en) 2003-06-10 2006-03-28 Sun Pharmaceutical Industries Limited Process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran acetamido-3-substituted-3-cephem-4-carboxylic acid
GB0317475D0 (en) * 2003-07-25 2003-08-27 Meditab Specialities Pvt Ltd Product
JP4025735B2 (ja) * 2003-08-21 2007-12-26 ローム アンド ハース カンパニー 水性系を処理する方法
GB0320312D0 (en) 2003-08-29 2003-10-01 Novartis Ag Purification process
CN100569765C (zh) * 2003-12-19 2009-12-16 杭州民生药业集团有限公司 西酞普兰中间体晶体碱
ITTO20050301A1 (it) * 2005-05-05 2006-11-06 Errekappa Euroterapici Spa Formulazioni liquide orali contenenti citalopram
WO2006123243A2 (en) * 2005-05-20 2006-11-23 Aurobindo Pharma Limited Pharmaceutical dosage forms comprising escitalopram in form of granules
TWI347942B (en) * 2005-06-22 2011-09-01 Lundbeck & Co As H Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
EP2502621A1 (de) 2005-06-27 2012-09-26 Valeant International (Barbados) SRL Kristalline Formen von Bupropion HBr
US20070276419A1 (en) 2006-05-26 2007-11-29 Fox Hollow Technologies, Inc. Methods and devices for rotating an active element and an energy emitter on a catheter
US8784440B2 (en) 2008-02-25 2014-07-22 Covidien Lp Methods and devices for cutting tissue
US8414604B2 (en) 2008-10-13 2013-04-09 Covidien Lp Devices and methods for manipulating a catheter shaft
BRPI1014721A2 (pt) 2009-04-29 2016-04-12 Tyco Healthcare métodos e dispositivos para cortar e raspar tecido
JP5281195B2 (ja) 2009-05-14 2013-09-04 コヴィディエン リミテッド パートナーシップ 簡単に清掃され得るアテレクトミー用カテーテルおよび使用の方法
KR20120079479A (ko) 2009-12-02 2012-07-12 타이코 헬스케어 그룹 엘피 조직 절단 장치 및 방법
US20110144673A1 (en) 2009-12-11 2011-06-16 Fox Hollow Technologies, Inc. Material removal device having improved material capture efficiency and methods of use
EP2742881B1 (de) 2010-06-14 2015-10-07 Covidien LP Materialentfernungsvorrichtung
US8920450B2 (en) 2010-10-28 2014-12-30 Covidien Lp Material removal device and method of use
KR101518151B1 (ko) 2010-11-11 2015-05-06 코비디엔 엘피 촬영용 가요성 디벌킹 카테터와, 사용 및 제조 방법
US8992717B2 (en) 2011-09-01 2015-03-31 Covidien Lp Catheter with helical drive shaft and methods of manufacture
US9532844B2 (en) 2012-09-13 2017-01-03 Covidien Lp Cleaning device for medical instrument and method of use
US9943329B2 (en) 2012-11-08 2018-04-17 Covidien Lp Tissue-removing catheter with rotatable cutter
WO2015200702A1 (en) 2014-06-27 2015-12-30 Covidien Lp Cleaning device for catheter and catheter including the same
US10314667B2 (en) 2015-03-25 2019-06-11 Covidien Lp Cleaning device for cleaning medical instrument
US10292721B2 (en) 2015-07-20 2019-05-21 Covidien Lp Tissue-removing catheter including movable distal tip
US10314664B2 (en) 2015-10-07 2019-06-11 Covidien Lp Tissue-removing catheter and tissue-removing element with depth stop
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2233970A (en) * 1941-03-04 Quinoline compound and process of
US2584429A (en) * 1950-12-29 1952-02-05 Rohm & Haas 1,1-diphenyl-4-tert.-amino-2-butyne-1-ols
GB1143702A (de) * 1965-03-18
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
DK213290D0 (da) 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
CA2120874E (en) * 1994-04-08 2002-01-08 Keshava Murthy Form of form 1 ranitidine
JP3526581B2 (ja) * 1997-07-08 2004-05-17 ハー・ルンドベック・アクティーゼルスカブ シタロプラムの製造方法
UA62985C2 (en) * 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
CZ292911B6 (cs) * 1997-11-11 2004-01-14 H. Lundbeck A/S Způsob výroby citalopramu
PL199423B1 (pl) 1998-10-20 2008-09-30 Lundbeck & Co As H Sposób wytwarzania citalopramu
ATE237604T1 (de) 1999-04-14 2003-05-15 Lundbeck & Co As H Verfahren zur herstellung von citalopram
ITMI991581A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991579A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
US6433196B1 (en) * 2000-02-17 2002-08-13 Sumika Fine Chemicals Co., Ltd. Production method of citalopram, intermediate therefor and production method of the intermediate
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US6977306B2 (en) * 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2806086A1 (fr) * 2000-03-13 2001-09-14 Lundbeck & Co As H Base cristalline du citalopram
GR1003796B (el) * 2000-03-13 2002-02-08 H. Lundbeck A/S Κρυσταλλικη βαση κιταλοπραμης.
EP1227088A1 (de) * 2000-03-13 2002-07-31 H.Lundbeck A/S Kristalline Base von Citalopram, und Hydrochlorid- oder Hydrobromidsalz davon
EP1152000A1 (de) * 2000-05-02 2001-11-07 SUMIKA FINE CHEMICALS Co., Ltd. Citalopramhydrobromidkristall und deren kristallisierungsverfahren
US6977306B2 (en) 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
EP1462447A2 (de) * 2000-12-22 2004-09-29 H. Lundbeck A/S Verfahren zur Herstellung von reinem Citalopram
EP1462447A3 (de) * 2000-12-22 2004-11-17 H. Lundbeck A/S Verfahren zur Herstellung von reinem Citalopram
WO2004094399A1 (en) * 2003-04-21 2004-11-04 Natco Pharma Ltd An improved process for the preparation of citalopram hydrobromide
US7560576B2 (en) 2005-06-22 2009-07-14 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
US7723533B2 (en) 2005-06-22 2010-05-25 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base

Also Published As

Publication number Publication date
HK1054750A1 (en) 2003-12-12
HUP0100531A3 (en) 2004-04-28
EP1169314B1 (de) 2002-09-04
ITMI20010406A1 (it) 2002-08-28
CA2360287A1 (en) 2001-09-20
US20040132808A1 (en) 2004-07-08
GB2357762A (en) 2001-07-04
NO315851B1 (no) 2003-11-03
TR200202185T2 (tr) 2002-12-23
CA2411732A1 (en) 2001-09-20
US20040167210A1 (en) 2004-08-26
IL147339A0 (en) 2002-08-14
US20050165244A1 (en) 2005-07-28
EP1169314B2 (de) 2011-06-01
NO312031B1 (no) 2002-03-04
US20010031784A1 (en) 2001-10-18
US20030078442A1 (en) 2003-04-24
AR029811A1 (es) 2003-07-16
DE60100022T3 (de) 2011-11-17
SI1227088T1 (en) 2003-12-31
EP1169314A1 (de) 2002-01-09
SE526022C2 (sv) 2005-06-14
FI109022B (fi) 2002-05-15
SE0103046D0 (sv) 2001-09-14
CN1429220A (zh) 2003-07-09
HU0100450D0 (en) 2001-04-28
MXPA02008793A (es) 2003-02-12
ATE250050T1 (de) 2003-10-15
DK1169314T3 (da) 2002-10-14
BR0109373A (pt) 2002-12-24
AU2001100197B4 (en) 2001-12-06
HUP0100531A2 (hu) 2002-01-28
DE10108042A1 (de) 2001-10-18
YU68802A (sh) 2005-11-28
NO20020356D0 (no) 2002-01-23
GB0105982D0 (en) 2001-05-02
NO20010619D0 (no) 2001-02-06
ES2173054T1 (es) 2002-10-16
SI1169314T1 (en) 2002-12-31
SE517136C2 (sv) 2002-04-16
UA74360C2 (uk) 2005-12-15
US20050165092A1 (en) 2005-07-28
DE10164687B4 (de) 2006-04-27
KR20020080486A (ko) 2002-10-23
HU0100531D0 (en) 2001-03-28
IES20010109A2 (en) 2002-02-20
CN1258530C (zh) 2006-06-07
ATE223396T1 (de) 2002-09-15
ES2173054T3 (es) 2002-12-16
NO20020356L (no) 2001-09-14
HU0001581D0 (en) 2000-06-28
WO2001068627A1 (en) 2001-09-20
GB2357762B (en) 2002-01-30
HRP20020756A2 (en) 2004-12-31
DK1227088T3 (da) 2003-12-22
DE60100786D1 (de) 2003-10-23
US20060247451A1 (en) 2006-11-02
IT1319645B1 (it) 2003-10-23
DE60100022T2 (de) 2003-03-06
CH691477A5 (de) 2001-07-31
CH691537A5 (de) 2001-08-15
FI20010156A0 (fi) 2001-01-25
SE0103046L (sv) 2001-11-14
ES2159491A1 (es) 2001-10-01
DE60100786T2 (de) 2004-07-15
SE0200730D0 (sv) 2002-03-12
FR2806086B1 (fr) 2003-05-09
NO20010619L (no) 2001-09-14
DE1227088T1 (de) 2003-02-06
SK285528B6 (sk) 2007-03-01
DE20121240U1 (de) 2002-07-04
AU746664B2 (en) 2002-05-02
PT1227088E (pt) 2003-12-31
NL1017413C1 (nl) 2001-09-13
AU2001100197A4 (en) 2001-09-20
SI1169314T2 (sl) 2011-08-31
FR2806086A1 (fr) 2001-09-14
FI20010225A (fi) 2001-09-14
ES2159491B1 (es) 2002-05-01
BG107065A (bg) 2003-05-30
ES2180471T1 (es) 2003-02-16
NL1016435C1 (nl) 2000-11-06
BE1013210A3 (fr) 2001-10-02
EA200200972A1 (ru) 2003-02-27
PT1169314E (pt) 2002-11-29
ZA200207148B (en) 2003-04-23
EP1227088B1 (de) 2003-09-17
SK13132002A3 (sk) 2003-01-09
GR1003796B (el) 2002-02-08
DE60100022D1 (de) 2002-10-10
IS5841A (is) 2001-09-14
IL158072A0 (en) 2004-03-28
CZ292077B6 (cs) 2003-07-16
CN1680350A (zh) 2005-10-12
AU3725201A (en) 2001-09-13
PL360158A1 (en) 2004-09-06
AT4364U1 (de) 2001-06-25
FI20010225A0 (fi) 2001-02-07
JP2003527383A (ja) 2003-09-16
CA2360287C (en) 2003-09-09
SE0200730L (sv) 2002-08-29
IL147339A (en) 2004-09-27
GB0102797D0 (en) 2001-03-21
DK173903B1 (da) 2002-02-11
EP1227088A1 (de) 2002-07-31
ITMI20002425A1 (it) 2002-05-09
ES2180471T3 (es) 2004-05-01
CZ2001808A3 (cs) 2002-01-16

Similar Documents

Publication Publication Date Title
DE20007303U1 (de) Kristalline Base von Citalopram
US4783471A (en) N-aralkyl piperidine methanol derivatives and the uses thereof
IE58460B1 (en) N-aralkyl piperidinemethanol derivatives
DE1964516A1 (de) 1-Substituierte 3-Amidopyrrolidine und Verfahren zu ihrer Herstellung
NZ594597A (en) Substituted piperidines as ccr3 antagonists
CA2075454A1 (en) Melt cocrystallised sorbitol/xylitol compositions
DE1643262C3 (de) i-Phenoxy^-hydroxy-S-alklyaminopropane, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE1964511A1 (de) 1-substituierte-3-Phenoxypyrrolidine und Verfahren zu ihrer Herstellung
GR3032253T3 (en) Novel 4-piperidinyl substituted lactames as neurokinin 2 receptor antagonists for the treatment of asthma
ATE147071T1 (de) 1,4-disubstituierte piperidinderivate, ihre herstellung und therapeutische verwendung
US5169096A (en) N-aralkyl-piperidine-methanol derivatives
HUE041842T2 (hu) Gyógyászati készítmény agymûködés javítására
CH675418A5 (de)
DE1964510A1 (de) 1-Substituierte-3-substituierte Phenoxypyrrolidine und Verfahren zu deren Herstellung
DE20116170U1 (de) Aspartatderivat des Amlodipins
DE3420193A1 (de) Neue substituierte pyrrolidinone, verfahren zu ihrer herstellung und arzneimittel
RU2020132922A (ru) Фармацевтическая композиция для предупреждения или лечения фиброза
DE20115218U1 (de) Amid-Derivat von Amlodipin
DE1931025A1 (de) ?-Carbamoyl-3-arolpyrrolidine und Verfahren zu deren Herstellung
DD153550A5 (de) Verfahren zur herstellung von neuer 1,2,4-oxadiazolin-5-on-derivaten
AT265256B (de) Verfahren zur Herstellung neuer 2-Aryltetrahydropyran-3-amine und ihrer Salze
AT319936B (de) Verfahren zur Herstellung von neuen Phenylimidazolidinonderivaten und ihren Salzen
DE2210620C2 (de) Bis-Phenoxypropanolamine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
NO20002049D0 (no) Hurtigoppløsende farmasøytisk preparat
AT333260B (de) Verfahren zur herstellung von neuen racemischen und optisch aktiven aminophenyl-athanolaminen

Legal Events

Date Code Title Description
R207 Utility model specification

Effective date: 20000831

R165 Request for cancellation or ruling filed
R165 Request for cancellation or ruling filed
R165 Request for cancellation or ruling filed
R150 Utility model maintained after payment of first maintenance fee after three years

Effective date: 20020121

R165 Request for cancellation or ruling filed
R165 Request for cancellation or ruling filed
R168 Utility model cancelled

Effective date: 20031105